DR Cleophas Chimbetete, MBChB, MPH - Newlands Clinic - Director: Research and Training

DR Cleophas Chimbetete

MBChB, MPH

Newlands Clinic

Director: Research and Training

Harare | Zimbabwe

Main Specialties: Epidemiology, Family Practice

DR Cleophas Chimbetete, MBChB, MPH - Newlands Clinic - Director: Research and Training

DR Cleophas Chimbetete

MBChB, MPH

Introduction

Primary Affiliation: Newlands Clinic - Harare , Zimbabwe

Specialties:

Research Interests:

Publications

26Publications

813Reads

118Profile Views

Drug Resistance Among Adolescents and Young Adults with Virologic Failure of First-Line Antiretroviral Therapy and Response to Second-Line Treatment.

AIDS Res Hum Retroviruses 2020 Jul 2;36(7):566-573. Epub 2020 Apr 2.

Department of Molecular Biology, Biomedical Research and Training Institute, Harare, Zimbabwe.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/AID.2019.0232DOI Listing
July 2020
2.325 Impact Factor

Zimbabwe's national third-line antiretroviral therapy program: Cohort description and treatment outcomes.

PLoS One 2020 2;15(3):e0228601. Epub 2020 Mar 2.

Institute of Global Health, University of Geneva, Geneva, Switzerland.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0228601PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7051055PMC
June 2020
3.234 Impact Factor

Characterizing the double-sided cascade of care for adolescents living with HIV transitioning to adulthood across Southern Africa.

J Int AIDS Soc 2020 01;23(1):e25447

Centre for Infectious Disease Epidemiology and Research, School of Public Health and Family Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jia2.25447DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6992508PMC
January 2020
5.090 Impact Factor

Gynecomastia in HIV-positive adult men receiving efavirenz-based antiretroviral therapy at Newlands clinic, Harare, Zimbabwe.

BMC Infect Dis 2019 Aug 13;19(1):715. Epub 2019 Aug 13.

Newlands Clinic, Harare, Zimbabwe.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12879-019-4332-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6693125PMC
August 2019
2 Reads
2.613 Impact Factor

A case report of untreatable HIV infection in Harare, Zimbabwe.

South Afr J HIV Med 2019 27;20(1):885. Epub 2019 Jun 27.

Institute of Global Health, University of Geneva, Geneva, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4102/sajhivmed.v20i1.885DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6620492PMC
June 2019
1 Read

HIV-1 Drug Resistance and Third-Line Therapy Outcomes in Patients Failing Second-Line Therapy in Zimbabwe.

Open Forum Infect Dis 2018 Feb 2;5(2):ofy005. Epub 2018 Feb 2.

Institute of Global Health, University of Geneva, Geneva, Switzerl.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ofid/ofy005DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5801603PMC
February 2018
12 Reads

New-onset type 2 diabetes mellitus among patients receiving HIV care at Newlands Clinic, Harare, Zimbabwe: retrospective cohort analysis.

Trop Med Int Health 2017 07 8;22(7):839-845. Epub 2017 Jun 8.

Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/tmi.12896DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5662202PMC
July 2017
74 Reads
2.329 Impact Factor

HIV drug resistance testing among patients failing second line antiretroviral therapy. Comparison of in-house and commercial sequencing.

J Virol Methods 2017 05 25;243:151-157. Epub 2016 Nov 25.

Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jviromet.2016.11.010DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5393912PMC
May 2017
32 Reads
1.883 Impact Factor

Protease Inhibitor Resistance in the First 3 Years of Second-Line Antiretroviral Therapy for HIV-1 in Sub-Saharan Africa.

J Infect Dis 2016 09 11;214(6):873-83. Epub 2016 Jul 11.

Amsterdam Institute for Global Health and Development, Department of Global Health Department of Internal Medicine, Division of Infectious Diseases, Academic Medical Center, University of Amsterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/infdis/jiw219DOI Listing
September 2016
55 Reads
5.997 Impact Factor

Authors' Reply: Early Initiation of Antiretroviral Therapy Among Young Children: A Long Way to Go.

J Acquir Immune Defic Syndr 2015 Oct;70(2):e71-2

*Institute of Social & Preventive Medicine (ISPM), University of Bern, Switzerland †Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA ‡Centre for Infectious Disease Research in Zambia, Lusaka, Zambia §Department of Medicine, Indiana University School of Medicine, Indianapolis, IN ‖Department of Pediatrics, Gabriel Toure Hospital, Bamako, Mali ¶Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand #Newlands Clinic, Harare, Zimbabwe **Maternal and Pediatric Infectious Disease Branch, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), Bethesda, MD ††Department of Pediatrics, College of Health Sciences, Moi University, Kenya ‡‡INSERM, French National Institute for Health and Medical Research, U897, Bordeaux, France §§Children's Hospital 1, Ho Chi Minh City, Vietnam ‖‖School of Public Health and Family Medicine, University of Cape Town Faculty of Health Sciences, South Africa.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/QAI.0000000000000773DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5339440PMC
October 2015
35 Reads
4.556 Impact Factor

Monitoring and switching of first-line antiretroviral therapy in adult treatment cohorts in sub-Saharan Africa: collaborative analysis.

Lancet HIV 2015 Jul 16;2(7):e271-8. Epub 2015 Jun 16.

Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland; Centre for Infectious Disease Epidemiology and Research, University of Cape Town, Cape Town, South Africa. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S2352-3018(15)00087-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4500741PMC
July 2015
79 Reads

Immunodeficiency in children starting antiretroviral therapy in low-, middle-, and high-income countries.

J Acquir Immune Defic Syndr 2015 Jan;68(1):62-72

*Institute of Social & Preventive Medicine (ISPM), University of Bern, Bern, Switzerland; †Department of Epidemiology, Harvard School of Public Health, Boston, MA; ‡Centre for Infectious Disease Research in Zambia, Lusaka, Zambia; §Department of Medicine, Indiana University School of Medicine, Indianapolis, IN; ‖Department of Pediatrics, Gabriel Toure Hospital, Bamako, Mali; ¶Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand; #Newlands Clinic, Harare, Zimbabwe; **Maternal and Pediatric Infectious Disease Branch, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), Bethesda, MD; ††Department of Pediatrics, College of Health Sciences, Moi University, Kenya; ‡‡INSERM, French National Institute for Health and Medical Research, U897, Bordeaux, France; §§Children's Hospital 1, Ho Chi Minh City, Vietnam; and ‖‖School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/QAI.0000000000000380DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4351302PMC
January 2015
45 Reads
4.556 Impact Factor

Incidence rate of Kaposi sarcoma in HIV-infected patients on antiretroviral therapy in Southern Africa: a prospective multicohort study.

J Acquir Immune Defic Syndr 2014 Dec;67(5):547-54

*Institute of Social and Preventive Medicine (ISPM), University of Bern, Bern, Switzerland; †Health Economics and Epidemiology Research Office, Department of Internal Medicine, School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa; ‡Division of Infectious Diseases, Department of Medicine, University of Stellenbosch and Tygerberg Academic Hospital, Cape Town, South Africa; §Department of Pediatrics and Child Health, University of Stellenbosch and Tygerberg Academic Hospital, Cape Town, South Africa; ‖Khayelitsha ART Program, Medecins Sans Frontieres, Cape Town, South Africa; ¶Independent Surgery, Gaborone, Botswana; #Newlands Clinic, Harare, Zimbabwe; **Centre for Infectious Disease Research in Zambia (CIDRZ), Lusaka, Zambia; ††Boston University School of Medicine, Section of Geriatrics, Boston, MA, USA; and ‡‡Centre for Infectious Disease Epidemiology and Research (CIDER), University of Cape Town, Cape Town, South Africa.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/QAI.0000000000000360DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4231535PMC
December 2014
24 Reads
4.556 Impact Factor

Prognosis of children with HIV-1 infection starting antiretroviral therapy in Southern Africa: a collaborative analysis of treatment programs.

Pediatr Infect Dis J 2014 Jun;33(6):608-16

From the *School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa; †School of Social and Community Medicine, University of Bristol, Bristol, United Kingdom; ‡Centre for Infectious Disease Research in Zambia, Lusaka, Zambia; §University of North Carolina, Chapel Hill, NC; ¶Newlands clinic, Harare, Zimbabwe; ‖Red Cross Children's Hospital and School of Child and Adolescent Health, University of Cape Town; **Médecins Sans Frontières (MSF) South Africa and Khayelitsha ART Programme, Cape Town; ††Sinikithemba Clinic, McCord Hospital, Durban; ‡‡Wits Reproductive Health and HIV Institute, University of the Witwatersrand, Johannesburg; §§Harriet Shezi Children's Clinic, Chris Hani Baragwanath Hospital, Soweto; ¶¶Africa Centre for Health and Population Studies, University of Kwazulu-Natal, Somkhele, South Africa; ‖‖Lighthouse Trust Clinic, Kamuzu Central Hospital, Lilongwe, Malawi and Liverpool School of Tropical Medicine, Liverpool, United Kingdom; ***Tygerberg Academic Hospital, University of Stellenbosch, Stellenbosch; †††Empilweni Services and Research Unit, Rahima Moosa Mother and Child Hospital, and University of the Witwatersrand, Johannesburg; ‡‡‡Gugulethu ART Programme and Desmond Tutu HIV Centre, University of Cape Town, Cape Town, South Africa; and §§§Institute of Social and Preventive Medicine (ISPM), University of Bern, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/INF.0000000000000214DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4349941PMC
June 2014
23 Reads
2.723 Impact Factor

Immunodeficiency at the start of combination antiretroviral therapy in low-, middle-, and high-income countries.

J Acquir Immune Defic Syndr 2014 Jan;65(1):e8-16

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/QAI.0b013e3182a39979DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3894575PMC
January 2014
120 Reads
4.556 Impact Factor

Tenofovir in second-line ART in Zambia and South Africa: collaborative analysis of cohort studies.

J Acquir Immune Defic Syndr 2012 Sep;61(1):41-8

Division of International and Environmental Health, Institute of Social and Preventive Medicine, University of Bern, Finkenhubelweg 11, CH-3012 Bern, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/QAI.0b013e3182632540DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3432418PMC
September 2012
29 Reads
4.556 Impact Factor

Top co-authors

Matthias Egger
Matthias Egger

Institute of Social and Preventive Medicine

14
Tinei Shamu
Tinei Shamu

Newlands Clinic

9
Olivia Keiser
Olivia Keiser

Institute of Social and Preventive Medicine

9
Hans Prozesky
Hans Prozesky

University of Stellenbosch and Tygerberg Academic Hospital

6
Sam Phiri
Sam Phiri

Lighthouse Trust

5
Matthew P Fox
Matthew P Fox

Center for Global Health and Development

5
Andrew Boulle
Andrew Boulle

School of Public Health and Family Medicine

5
Janet Giddy
Janet Giddy

Massachusetts General Hospital

4
Robin Wood
Robin Wood

Institute of Infectious Disease and Molecular Medicine

4